Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Rendon-Garcia

Internal Medicine Savannah, GA Medical Doctor

NPI 1083650972 CMS profile 49194

11909D McAuley Dr, Savannah, GA 31419

Open in the dashboard

General payments

$12,473

878 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Rendon-Garcia of Savannah, GA is reported in the CMS Open Payments database as having received $12,473 across 878 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,141 118
2024 General $1,712 103
2023 General $1,782 114
2022 General $1,758 129
2021 General $1,805 139
2020 General $1,621 127
2019 General $1,655 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Rendon-Garcia
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jose Rendon-Garcia were reported at $2,141. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jose Rendon-Garcia Internal Medicine median Middle half National median
2019 $1,655 $159 $48–$570 $163
2020 $1,621 $119 $33–$402 $114
2021 $1,805 $135 $37–$521 $132
2022 $1,758 $141 $42–$496 $149
2023 $1,782 $149 $45–$519 $160
2024 $1,712 $154 $47–$537 $164
2025 $2,141 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,874 171 payments
  2. AbbVie, Inc. $1,543 123 payments
  3. AstraZeneca Pharmaceuticals LP $1,401 62 payments
  4. Lilly USA, LLC $1,164 91 payments
  5. Pfizer Inc. $660 52 payments
  6. Amgen Inc. $637 40 payments
  7. Merck Sharp & Dohme Corporation $566 38 payments
  8. GlaxoSmithKline, LLC. $503 37 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $444 25 payments
  10. Novartis Pharmaceuticals Corporation $409 24 payments
  11. Other $3,272 215 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,447 876 payments
  2. Education $27 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,322 116 payments
  2. RYBELSUS $1,187 102 payments
  3. FARXIGA $1,150 47 payments
  4. MOUNJARO $617 47 payments
  5. VRAYLAR Neuroscience $553 44 payments
  6. Repatha $519 33 payments
  7. Otezla $464 27 payments
  8. VRAYLAR Neuroscience $449 46 payments
  9. TRULICITY $423 35 payments
  10. UBRELVY $403 31 payments
  11. Other $11,346 767 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 151 drugs

Part D claims

10,202

Median for Internal Medicine: 777

Drug cost

$1,095,236

Median for Internal Medicine: $73,373

Branded share of claims

23.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 170 $186,566
Farxiga Dapagliflozin Propanediol Brand 218 $175,149
Trulicity Dulaglutide Brand 69 $88,002
Ozempic Semaglutide Brand 76 $82,906
Januvia Sitagliptin Phosphate Brand 56 $57,533
Jardiance Empagliflozin Brand 61 $45,891
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $43,907
Linzess Linaclotide Brand 49 $35,848
Eliquis Apixaban Brand 29 $33,019
Rybelsus Semaglutide Brand 19 $30,893

The 10 drugs with the highest cost, of 151 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$57,720

Of which drugs: $2,807

Medicare patients

271

Average age 75

Services billed

1,860

145 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Arthritis 45%
Chronic kidney disease 19%
COPD 19%
Cancer 19%
Ischemic heart disease 16%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 20 21 $1,698
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 191 $130
Injection, ceftriaxone sodium, per 250 mg J0696 Office 33 71 $23
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 42 224 $18
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 28 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$185 19 —
AIRSUPRA
$128 — —
MOUNJARO
$112 170 —
RYBELSUS
$108 19 —
Ozempic
$108 76 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

878 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record